Yahoo · Aug 20, 2026
MediWound (MDWD) Q2 2026 Earnings Call Transcript
EscharEx advances Phase III enrollment while manufacturing facility nears regulatory completion.
NASDAQ · MDWD
MediWound Ltd.
Healthcare · Biotechnology
$13.24
Down-$0.49 (-3.67%)
Updated Aug 28, 2026, 5:33 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 209.54M
- P/E ratio
- -7.4
- Dividend yield
- 0.00%
- 52-week range
- $12.61 – $20.30
- Volume
- 196.22K
- Avg. volume
- 79.29K
Price performance
MDWD price history
1M range · 21 trading sessions · Daily adjusted prices
MDWD closed at $13.24 after 21 trading sessions, down 6.10% for the selected period.
- Last close
- $13.24
- Period change
- -6.10%
- Period low
- $12.70
- Period high
- $14.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $12.72 | $13.25 | $12.72 | $13.24 | 196.22K |
| Aug 26, 2026 | $13.00 | $13.085 | $12.61 | $12.70 | 209.56K |
| Aug 25, 2026 | $13.07 | $13.13 | $12.85 | $12.97 | 80.36K |
| Aug 24, 2026 | $13.19 | $13.27 | $12.86 | $13.00 | 101.56K |
| Aug 21, 2026 | $13.15 | $13.32 | $13.065 | $13.21 | 79.83K |
| Aug 20, 2026 | $13.60 | $13.60 | $13.06 | $13.115 | 81.39K |
| Aug 19, 2026 | $13.75 | $13.78 | $13.53 | $13.59 | 53.61K |
| Aug 18, 2026 | $13.44 | $13.80 | $13.44 | $13.64 | 56.42K |
| Aug 17, 2026 | $13.52 | $13.92 | $13.29 | $13.39 | 74.01K |
| Aug 14, 2026 | $13.52 | $13.7228 | $13.40 | $13.56 | 46.75K |
| Aug 13, 2026 | $14.06 | $14.41 | $13.46 | $13.53 | 62.27K |
| Aug 12, 2026 | $14.01 | $14.12 | $13.81 | $13.91 | 50.19K |
| Aug 11, 2026 | $13.89 | $14.10 | $13.80 | $13.93 | 38.99K |
| Aug 10, 2026 | $14.36 | $14.525 | $13.80 | $13.83 | 79.61K |
| Aug 7, 2026 | $14.29 | $14.5548 | $14.245 | $14.39 | 58.61K |
| Aug 6, 2026 | $14.19 | $14.5799 | $14.19 | $14.28 | 33.2K |
| Aug 5, 2026 | $14.38 | $14.555 | $14.17 | $14.19 | 65.69K |
| Aug 4, 2026 | $14.20 | $14.4849 | $14.05 | $14.30 | 66.89K |
| Aug 3, 2026 | $14.17 | $14.28 | $13.92 | $14.22 | 60.57K |
| Jul 31, 2026 | $14.10 | $14.565 | $13.91 | $14.12 | 75.36K |
| Jul 30, 2026 | $14.30 | $14.5825 | $14.02 | $14.10 | 68.13K |
Latest MDWD news
The latest Smart Investors Daily articles mentioning MDWD.
Stock researchCompany · Overview
MDWD research
Overview
Company profile and research snapshot.
Company profile
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Outperform | — |
| May 28, 2026 | Oppenheimer | Outperform | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | — |
| May 22, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $32 to $30.
Yahoo · Aug 14, 2026
MediWound Ltd. Q2 2026 Earnings Call Summary
Moby summary of MediWound Ltd.'s Q2 2026 earnings call
Yahoo · Aug 13, 2026
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...
MediWound Ltd (MDWD) reaffirms 2026 guidance with record NexoBrid quarterly sales, advances EscharEx Phase 3 trial, and expands market opportunity to $1.05 billion in peak annual sales.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
